华西医学

华西医学

精准医疗助力结核病防治

查看全文

结核病是世界性重大的公共卫生问题。随着“精准医学”概念的提出,结核病的防治被带入精准医学的时代,结核病的精准诊断、治疗和患者管理方面取得了许多重要进展,但是还存在诸多挑战。要抓住机遇,用精准医疗的理念建立并完善新型结核病防治措施,建立患者的精准诊断标准,制订精准的治疗方案,早期鉴定治疗失败的高风险人群,及时开展精准的个体干预措施,提高结核病患者的治疗水平,从而有效阻断结核病在人群中的传播,为达成 2035 年“消灭结核病”的宏伟目标不懈努力。

Tuberculosis (TB) is one of the major public health concerns worldwide. Since the development of precision medicine, the filed regarding TB control and prevention has been brought into the era of precision medicine. Although great progress has been achieved in the accurate diagnosis, treatment and management of TB patients, we have to face several challenges. We should seize the opportunity, and develop and improve novel measures in TB prevention on the basis of precision medicine. The accurate diagnosis criteria, treatment regimen and management of TB patients should be carried out according to the standard of precision medicine. We aim to improve the treatment of TB patients and prevent the transmission of TB in the community, thereby contributing to the achievement of the End TB Strategy by 2035.

关键词: 精准医疗; 结核病; 防治

Key words: Precision medicine; Tuberculosis; Prevention

引用本文: 逄宇, 李亮. 精准医疗助力结核病防治. 华西医学, 2018, 33(8): 921-925. doi: 10.7507/1002-0179.201807059 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med, 2015, 372(9): 793-795
2. 王旭阳, 刘其会, 张文宏. 精准医疗与结核病. 微生物与感染, 2017, 12(6): 328-332
3. 武爱文, 季加孚. 实施精准医学的机遇与挑战. 中华临床实验室管理电子杂志, 2015, 3(3): 129-131
4. Dorman S. Advances in the diagnosis of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis, 2015, 19(5): 504-516
5. Ryu YJ. Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis (Seoul), 2015, 78(2): 64-71
6. Ou X, Li Q, Xia H, et al. Diagnostic accuracy of the PURE-LAMP test for pulmonary tuberculosis at the county-level laboratory in China. PLoS One, 2014, 9(5): e94544
7. Pang Y, Wang Y, Zhao S, et al. Evaluation of the xpert MTB/RIF assay in gastric lavage aspirates for diagnosis of smear-negative childhood pulmonary tuberculosis. Pediatr Infect Dis J, 2014, 33(10): 1047-1051
8. World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. Geneva: World Health Organization, 2013. http://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf;sequence=1
9. 中华医学会结核病学分会. 中国结核病病理学诊断专家共识. 中华结核和呼吸杂志, 2017, 40(6): 419-425
10. 张海青, 车南颖. 我国结核病病理学诊断和研究的现状与展望. 中国防痨杂志, 2014, 36(9): 793-797
11. Cattamanchi A, Huang L, Worodria W, et al. Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med, 2011, 183(4): 547-551
12. 安军, 逄宇. 重视新型实验室技术助力菌阴肺结核诊断. 中国防痨杂志, 2018, 40(4): 345-347
13. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis, 2012, 12(1): 103
14. World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance. Geneva: World Health Organization, 2015. http://apps.who.int/iris/bitstream/handle/10665/193633/9789241509633_eng.pdf?sequence=1
15. Liu C, Zhao Z, Fan J, et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci USA, 2017, 114(15): 3969-3974
16. Click ES, Murithi W, Ouma GS, et al. Detection of apparent cell-free M. tuberculosis DNA from plasma. Sci Rep, 2018, 8(1): 645
17. Che N, Yang X, Liu Z, et al. Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. J Clin Microbiol, 2017, 55(5): 1526-1532
18. Kosaka N, Yoshioka Y, Katsuda T, et al. Exosome in disease biology, diagnosis, and therapy. Inflamm Regen, 2014, 34(5): 233-239
19. Smith VL, Cheng Y, Bryant BR, et al. Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection. Sci Rep, 2017, 7: 43578
20. 刘君, 裴豪, 蒯守刚, 等. 结核分枝杆菌实验室耐药诊断技术进展. 现代预防医学, 2014, 41(20): 3775-3777
21. Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep, 2016, 6: 25330
22. Pang Y, Xia H, Zhang Z, et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol, 2013, 51(6): 1707-1713
23. Li Q, Dong HY, Pang Y, et al. Multicenter evaluation of the molecular line probe assay for multidrug resistant Mycobacterium tuberculosis detection in China. Biomed Environ Sci, 2015, 28(6): 464-467
24. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. (2008-06-27)[2018-07-26]. http://www.who.int/tb/features_archive/policy_statement.pdf
25. Zhang Z, Wang Y, Pang Y, et al. Comparison of different drug susceptibility test methods to detect rifampin heteroresistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(9): 5632-5635
26. Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis, 2015, 15(10): 1193-1202
27. Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb), 2007, 87(6): 551-556
28. Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res, 2013, 3(1): 1-2
29. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23): 2151-2160
30. Quan D, Nagalingam G, Payne R, et al. New tuberculosis drug leads from naturally occurring compounds. Int J Infect Dis, 2017, 56: 212-220
31. Abate G, Hoft DF. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther, 2016, 5: 37-45
32. Yang XY, Chen QF, Li YP, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One, 2011, 6(9): e23826
33. Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci, 2015, 11(3): 584-590
34. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311(5768): 1770-1773
35. Getahun H, Matteelli A, Chaisson RE. Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372(22): 2127-2135
36. Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297
37. Liu X, Lewis JJ, Zhang H, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med, 2015, 12(9): e1001876
38. 任思冲, 周海琴, 彭萍. 大数据挖掘促进精准医学发展. 国际检验医学杂志, 2015, 36(23): 3499-3501
39. Jaeger S, Karargyris A, Candemir S, et al. Automatic tuberculosis screening using chest radiographs. IEEE Trans Med Imaging, 2014, 33(2): 233-245